z-logo
open-access-imgOpen Access
Single Nucleotide Polymorphisms rs2227284, rs2243283 and rs2243288 in the IL-4 Gene Show no Association with Susceptibility to Chronic Hepatitis B in a Chinese Han Population
Author(s) -
Qin Zhou,
Yufeng Gao,
Xiaomiao Zhao,
Faming Pan,
Xu Li
Publication year - 2014
Publication title -
infection international/infection international (electronic edition)
Language(s) - English
Resource type - Journals
eISSN - 2544-0349
pISSN - 2095-2244
DOI - 10.1515/ii-2017-0068
Subject(s) - single nucleotide polymorphism , genotype , hepatitis b virus , odds ratio , haplotype , allele , allele frequency , medicine , biology , immunology , virology , gene , genetics , virus
Objective To investigate the relationship between single nucleotide polymorphisms (SNPs) of the interleukin-4 (IL-4) gene and outcome of hepatitis B virus (HBV) infection in a Chinese Han population. Methods Total of 501 patients with chronic hepatitis B virus (HBV) infection and 301 controls with selflimiting HBV infection were studied. Three tag SNPs in the IL-4 gene (rs2227284G/T, rs2243283C/G and rs2243288A/G) were genotyped by the Multiplex snapshot technique. The genotype and allele frequencies were calculated and analyzed. Results The three SNPs showed no significant genotype/allele associations with chronic HBV infection. Overall allele P values were: rs2227284, P = 0.655, odds ratio (OR) [95% confidence interval (CI)] = 1.070 (0.793-1.445); rs2243283, P = 0.849, OR (95% CI) = 0.976 (0.758-1.257); rs2243288, P = 0.659, OR (95% CI) = 1.060 (0.818-1.375). Overall genotype P values were: rs2227284, P = 0.771; rs2243283, P = 0.571; rs2243288, P = 0.902. There were no statistically significant differences between patients with chronic HBV infection and controls. Haplotypes generated by these three SNPs also had no significant differences between the two groups. Conclusions The three tag SNPs of IL-4 were not associated with the outcome of HBV infection in the Han Chinese population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here